Study S001388

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07245771
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 104
Start: 2025-11-04
Primary completion: 2027-02-15
Lead sponsor: Ikaria Bioscience Pty Ltd
Conditions: Obesity &Amp; Overweight
Interventions: DRUG:RN3161; DRUG:Placebo Control; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Blood Pressure [180 Days]
ECG PR interval [180 days]
Physical Examination [180 days]
Blood Chemistry Laboratory [180 days]
Adverse Events [180 days]
Heart Rate [180 days]
ECG QRS Complex [180 days]
ECG QT interval [180 days]
Blood Hematology Laboratory [180 days]
Blood Coagulation Laboratory [180 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.